# US 2012/0129944 A1 · Stabilized composition comprising at least one adrenergic compound > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2012/0129944 A1 - Document ID: US20120129944A1 - Status: Published application - Kind: A1 - Application number: 13/376,021 - Filed: 2010-06-03 - Published: 2012-05-24 - Earliest claimed: 2009-06-04 - Assignees: Alk AG - Inventors: Alan J. Baillie; Kenneth MacDonald; Pamela Porteous; Simon Hendry - Web page: https://patentgrep.com/patent/US20120129944A1 ## CPC - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} - A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/02: Inorganic compounds - A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 11/06: Antiasthmatics - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A stabilised composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound. ## Claims ### Claim 1 A liquid pharmaceutical composition comprising an adrenergic compound wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a meta bisulfite and a sulfite compound, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said liquid composition is in the range of about 2.0-5.0. ### Claim 2 (canceled) ### Claim 3 (canceled) ### Claim 4 (canceled) ### Claim 5 (depends on 1) The pharmaceutical composition according to claim 1, wherein the antioxidant is selected from the group consisting of sodium bisulfite and sodium metabisulfite. ### Claim 6 (depends on 1) The pharmaceutical composition according to claim 1, wherein the antioxidant is sodium metabisulfite. ### Claim 7 (depends on 1) The pharmaceutical composition according to claim 1, wherein the molar ratio of the at least one adrenergic compound to the at least one antioxidant is in the range of 0.75 to 1.25. ### Claim 8 (depends on 1) The pharmaceutical composition according to claim 1, having a pH in the range of 2.5-4.5. ### Claim 9 (depends on 8) The pharmaceutical composition according to claim 8, wherein the pH is in the range of 3.3-3.5. ### Claim 10 (depends on 1) The pharmaceutical composition according to claim 1, further comprising one or more excipients or additives. ### Claim 11 (depends on 1) The pharmaceutical composition according to claim 1, comprising 2.0 mg/ml epinephrine acid tartrate, 6.0 mg/ml sodium chloride, and 0.57 mg/ml sodium metabisulfate, and having a pH of 3.4. ### Claim 12 A method for stabilizing a liquid pharmaceutical composition comprising an adrenergic compound, comprising the steps of i) providing a solution of an adrenergic compound, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, ii) adding at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite, and a sulfite compound, iii) adjusting the pH thereof to a value in the range 2.0-5.0 optionally by addition of an acid or a base, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30. ### Claim 13 The method of stabilizing a liquid pharmaceutical composition which comprises combining at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite, and a sulfite compound and epinephrine or a physiologically acceptable salt thereof, wherein the molar ratio of the epinephrine or a physiologically acceptable salt thereof to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said liquid composition is in the range of about 2.0-5.0. ### Claim 14 A kit comprising: i) a liquid pharmaceutical composition comprising an adrenergic compound, wherein the adrenergic compound is epinephrine or a physiologically acceptable sale thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said liquid composition is in the range of about 2.0-5.0, and ii) an administration device. ### Claim 15 (depends on 14) The kit according to claim 14 wherein the administration device is an ampoule or an auto-injector. ### Claim 16 A method of improving at least one symptom of a medical condition requiring an adrenergic compound in an individual in need thereof, which comprises administering to the individual a liquid pharmaceutical composition comprising an adrenergic compound, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said liquid composition is in the range of about 2.0-5.0. ### Claim 17 A method of treating anaphylaxis in an individual comprising administering to the individual a liquid pharmaceutical composition comprising an adrenergic compound, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said liquid composition is in the range of about 2.0-5.0. ### Claim 18 (canceled) ### Claim 19 (canceled) ### Claim 20 A liquid medicament comprising an adrenergic compound wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and wherein the pH of said medicament is 2.0 and 5.0.